LTRC - LTRC Personnel

LTRC Personnel

Primary Investigators:

James Geller, MD
Medical Director, Liver and Kidney Tumors Program
James.Geller@cchmc.org

James I. Geller, MD, completed undergraduate training at Dartmouth College, medical training at the Tel Aviv University, residency training in pediatrics at New York Medical College and pediatric hematology / oncology training at St. Jude Children’s Research Hospital. His current appointment is with Cincinnati Children’s Hospital Medical Center within the University of Cincinnati in the capacity of Professor of Pediatrics.

Dr. Geller is the Medical Director of the Liver and Renal Tumor Programs and Co-Director of the Retinoblastoma Program at CCHMC. His primary academic interest is the development of novel therapy options for infants, children, adolescents, and young adults with solid tumors. At the institutional level, this is achieved through direct patient care and by leading our teams in clinical and research efforts in his specialty areas at Cincinnati Children’s Hospital Medical Center. At the national level, Dr. Geller is a member of the Children’s Oncology Group (COG) Liver Tumor and Renal Tumor Committees; serving as co-Chair of the International Hepatoblastoma study, AHEP1531/PHITT, Chair of several kidney tumor studies in children with high-risk/relapsed kidney tumors, and COG Chair of the Renal Tumor Committee. Dr. Geller has served as a member of the COG Developmental Therapeutics Committee for many years, including participation as a liaison to the Pediatric Preclinical Testing Program and on the Agent Selection Committee for the Pediatric MATCH study.

Allison O’Neill, MD
Clinical Director, Solid Tumor Program
Medical Director, Liver Tumor Center of Excellence
Allison_ONeill@dfci.harvard.edu

Allison F. O’Neill, MD completed undergraduate training at Yale University, medical training at Albert Einstein University, residency training at Boston Children’s Hospital and pediatric hematology/oncology training at Dana-Farber and Boston Children’s Hospital Cancer and Blood Disorders Center. Her current appointment is with Dana-Farber Cancer Institute within Harvard University in the capacity of Assistant Professor of Pediatrics.

Dr. O’Neill is the Clinical Director of the Pediatric Solid Tumor Program and Medical Director of the Liver Tumor Center of Excellence at Dana-Farber Cancer Institute and Boston Children’s Hospital. In her role as Director of the Solid Tumor Program, her overarching responsibilities include guiding clinical research initiatives in concert with the experimental therapeutics division and cultivating a programmatic mission surrounding multidisciplinary clinics, visibility in the rare tumor space, and expanding initiatives in immunotherapy. The Liver Tumor Center of Excellence collaboratively unites individuals of a broad multidisciplinary expertise to deliver care to children with these exceptionally rare tumors. At the national level, Dr. O’Neill is the Chair of the Children’s Oncology Group Liver Tumor Committee and co-authored the HCC arm of the current International Hepatoblastoma study, AHEP1531/PHITT. Dr. O’Neill has designed two prospective studies for pediatric patients with relapsed HCC, a multi-institutional protocol studying the efficacy of checkpoint inhibition and a sponsor-initiated single-institute trial studying an engineered T-cell targeting AFP.